TY - JOUR
T1 - Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer
T2 - Recent perspectives
AU - Walker, Caroline H.
AU - Drew, Barbara A.
AU - Antoon, James W.
AU - Kalueff, Alan V.
AU - Beckman, Barbara S.
PY - 2012/2
Y1 - 2012/2
N2 - With an estimated 207,090 patients diagnosed with breast cancer in 2010, the role of chemotherapy-induced cognitive impairment is of growing importance. Studies to determine the impact of chemotherapy-induced cognitive impairment have been hindered by difficulties in study-design, in particular, study methodology. Here, we present a review of existing studies and discuss several mechanisms for chemotherapy-induced neurocognitive impairment in breast cancer patients, such as direct neurotoxic injury, telomere shortening, oxidative stress, cytokine dysregulation, estrogen-mediated effects, and the role of certain genetic polymorphisms. Decreased estrogen levels may serve as a link between multiple mechanisms potentiating the effects of the chemotherapy-induced cognitive impairment.
AB - With an estimated 207,090 patients diagnosed with breast cancer in 2010, the role of chemotherapy-induced cognitive impairment is of growing importance. Studies to determine the impact of chemotherapy-induced cognitive impairment have been hindered by difficulties in study-design, in particular, study methodology. Here, we present a review of existing studies and discuss several mechanisms for chemotherapy-induced neurocognitive impairment in breast cancer patients, such as direct neurotoxic injury, telomere shortening, oxidative stress, cytokine dysregulation, estrogen-mediated effects, and the role of certain genetic polymorphisms. Decreased estrogen levels may serve as a link between multiple mechanisms potentiating the effects of the chemotherapy-induced cognitive impairment.
KW - Breast cancer
KW - Chemobrain
KW - Cognitive impairment
KW - Pharmacology, Chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84856098600&partnerID=8YFLogxK
U2 - 10.3109/07357907.2011.636116
DO - 10.3109/07357907.2011.636116
M3 - Article
C2 - 22250588
AN - SCOPUS:84856098600
SN - 0735-7907
VL - 30
SP - 135
EP - 148
JO - Cancer Investigation
JF - Cancer Investigation
IS - 2
ER -
